Clabribine (MAVENCLAD) for RRMS – PBAC Review
Medication Subsidy (PBAC), Medications and Treatments, Disease Modifying Therapy, DMT, Pharmaceutical Benefits Advisory Committee, PBAC
Ocrelizumab (Ocrevus) for PPMS – PBAC Review
Medication Subsidy (PBAC), Medications and Treatments, Disease Modifying Therapy, DMT, Pharmaceutical Benefits Advisory Committee, PBAC
OCREVUS (Ocrelizumab) for primary progressive MS – November 2017 PBAC Agenda
Medication Subsidy (PBAC), Medications and Treatments, Disease Modifying Therapy, DMT, Pharmaceutical Benefits Advisory Committee, PBAC
Superannuation Assessing Efficiency and Competitiveness
Economic, Poverty, Superannuation
Black triangle scheme
Medical Regulations (TGA), Medications and Treatments, TGA, Therapeutic Goods Administration
Ocrelizumab PBAC submission – July 2017
Medication Subsidy (PBAC), Medications and Treatments, Disease Modifying Therapy, DMT, Pharmaceutical Benefits Advisory Committee, PBAC
